Theranostic research of radiolabeled prostate-specific membrane antigen ligands in metastatic castra-tion-resistant prostate cancer / 中华核医学与分子影像杂志

ABSTRACT

Prostate cancer is the most common cancer among males. Advanced prostate cancer could develop into metastatic castration-resistant prostate cancer (mCRPC), which is a challenge in the di-agnosis and treatment. The prognosis and quality of life of patients can be significantly improved by using ra-diolabeled prostate-specific membrane antigen ( PSMA) ligands for localization and targeted therapy of mCRPC. This review summarizes the research progress of radiolabeled PSMA ligands in theranostics of mCRPC including SPECT imaging, PET imaging, and brachytherapy.